In this video, Adriana Rossi, MD, assistant professor of medicine at Mount Sinai, discusses the state of the pipeline in multiple myeloma.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.
Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline
AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline
Eliminating KRAS: Why targeted protein degraders could redefine what’s possible in cancer
EU and US advisers split over AstraZeneca breast cancer drug
ASCO26: 5 data snapshots ahead of the year’s biggest cancer drug meeting
AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026
At ASCO, drugmakers to offer options after Keytruda in head and neck cancer
Carolyn was on the brink of death. Her recovery has doctors ‘shooting for a cure’
AstraZeneca, Daiichi beat Gilead to first-line TNBC with FDA nod for Datroway
In this video, Adriana Rossi, MD, assistant professor of medicine at Mount Sinai, discusses future research directions in…
In this video, Adriana Rossi, MD, assistant professor of medicine at Mount Sinai, highlights upcoming clinical trials in multiple…
In this video, Adriana Rossi, MD, assistant professor of medicine at Mount Sinai, highlights challenges in multiple myeloma…
VIDEO: Treatment options vary for relapsed, refractory multiple myeloma
VIDEO: Immunotherapies offer new opportunities in relapsed, refractory myeloma
VIDEO: CAR-T in the frontline setting, other promising areas of research in myeloma
